Previsão

O preço-alvo médio dos analistas é € 1.193,79 (+17,28%). A mediana é € 1.223,06 (+20,16%).

Comprar	33
Manter	9
Vender	3

Notícias Ir para o feed de notícias

Eli Lilly: Foundayo high dose shows prognostically lower risk for type 2 diabetes and cardiovascular disease

A post hoc analysis of the phase‑3 ATTAIN‑1 study estimates that the maximum Foundayo dose of 17.2 mg is associated with a 57 percent lower projected ten‑year risk for type 2 diabetes and an 18 percent lower projected risk for cardiovascular disease compared with placebo. These figures are projected risks and do not prove that the diseases actually occur less often. The FDA approved Foundayo in April for weight management; the new data strengthen Lilly’s position versus Novo’s oral GLP‑1 therapy Wegovy, although a direct head‑to‑head comparison is lacking. » Mais em deraktionaer.de
Eli Lilly reports promising weight-loss combo but higher adverse events weigh on stock

Eli Lilly disclosed mid-stage data for EloraTZP, a combo of eloralintide and tirzepatide, showing greater mean weight loss than high-dose tirzepatide alone (23.3% vs. 14.8%). However, the trial also recorded more frequent adverse events with the combination, prompting caution about its tolerability and suggesting the therapy may serve a niche subset of patients. Lilly plans an optimized dose-escalation schedule for Phase 3 to address tolerability concerns while continuing development of other obesity candidates like retatrutide. » Mais em cnbc.com
Eli Lilly combo of amylin drug and tirzepatide delivers greater weight loss in Phase 2 trial

Eli Lilly said a mid-stage trial of an experimental combination regimen—eloralintide (amylin) plus low-dose tirzepatide—produced up to 23.3% weight loss over 48 weeks versus 14.8% for a 15 mg tirzepatide dose and 12.3% for eloralintide alone. The combo also reduced A1C by up to 2.9% compared with 2.4% for higher-dose tirzepatide. Treatment discontinuations for side effects, mainly gastrointestinal, were higher with the combination; Lilly plans Phase 3 trials and a co-formulation by the end of 2026 with adjusted dosing to improve tolerability. » Mais em cnbc.com

Dividendos históricos Dividendos

Todos os indicadores de dividendos Todos os indicadores

Em 2026, Eli Lilly & Co já distribuiu € 4,48 em dividendos. A última distribuição ocorreu em setembro.

Dados financeiros da empresa

No último trimestre, Eli Lilly & Co registou receitas de € 20,13 bi e um ganho líquido de € 6,22 bi

(EUR)	junho de 2026	YoY
Receitas	20,13 bi	52,50%
Ganho bruto	17,27 bi	55,24%
Ganho líquido	6,22 bi	29,44%
EBITDA	11,38 bi	78,91%

Dados fundamentais

Métrica	Valor
Capitalização bolsista	€ 968,55 bi
Número de ações	941,74 mi
Máximo/mínimo de 52 semanas	€ 1.148,97 - € 696,73
Rentabilidade de dividendos	0,56%
Dividendos TTM	€ 5,76
Beta	0,50
PER (PE Ratio)	38,71
PEG (PEG Ratio)	0,41
P/VC (PB Ratio)	30,48
P/V (PS Ratio)	13,68

Perfil da empresa

Eli Lilly and Company erforscht, entwickelt und vermarktet weltweit Humanarzneimittel. Es bietet Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, Insulin Lispro, Insulin Lispro Protamin, Insulin Lispro Mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R und Humulin U-500 für Diabetes; und Jardiance, Trajenta und Trulicity für Typ-2-Diabetes. Das Unternehmen bietet Alimta für nicht-kleinzelligen Lungenkrebs (NSCLC) und bösartiges Pleuramesotheliom; Cyramza für metastasierenden Magenkrebs, Adenokarzinom des gastroösophagealen Übergangs, metastasierenden NSCLC, metastasierenden kolorektalen Krebs und hepatozelluläres Karzinom; Erbitux für kolorektale Karzinome und verschiedene Kopf- und Halskrebsarten; Retevmo für metastasierten NSCLC, medullären Schilddrüsenkrebs und Schilddrüsenkrebs; Tyvyt für rezidivierte oder refraktäre klassische Hodgkin-Lymphome und nicht-squamösen NSCLC; und Verzenio für HR+, HER2- metastasierten Brustkrebs, knotenpositiven und frühen Brustkrebs. Es bietet Olumiant für rheumatoide Arthritis und Taltz für Plaque-Psoriasis, psoriatische Arthritis, ankylosierende Spondylitis und nicht-radiographische axiale Spondylarthritis. Das Unternehmen bietet Cymbalta für depressive Störungen, diabetische periphere neuropathische Schmerzen, generalisierte Angststörungen, Fibromyalgie und chronische Muskel-Skelett-Schmerzen; Emgality für Migräne-Prävention und episodische Cluster-Kopfschmerzen; und Zyprexa für Schizophrenie, bipolare Störung und bipolare Erhaltung. Seine Bamlanivimab und Etesevimab und Bebtelovimab für COVID-19; Cialis für erektile Dysfunktion und benigne Prostatahyperplasie; und Forteo für Osteoporose. Das Unternehmen arbeitet mit der Incyte Corporation, Boehringer Ingelheim Pharmaceuticals, Inc., AbCellera Biologics Inc., Junshi Biosciences, Regor Therapeutics Group, Lycia Therapeutics, Inc., Kumquat Biosciences Inc., Entos Pharmaceuticals Inc. und Foghorn Therapeutics Inc. zusammen. Eli Lilly and Company wurde 1876 gegründet und hat seinen Hauptsitz in Indianapolis, Indiana.

Nome	Eli Lilly & Co
CEO	David A. Ricks
Sede	Indianapolis, in EUA
Site	lilly.com
Setor	Cuidados de saúde
Indústria	Produtos farmacêuticos
Entrada em bolsa	01/06/1972
Colaboradores	50.000